Detail akcie AdaptimmTher Sp ADR online

Business Summary: Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. The engineered T cell receptor (TCR) platform, which the Company is developing for personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers. It is focused on the commercialization of TECELRA, which is a genetically modified autologous T-cell immunotherapy indicated for the treatment of adults with advanced synovial sarcoma. Its second T-cell immunotherapy, letetresgene autoleucel (lete-cel), targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). It has filed an IND for ADP-5701 for a Phase I trial in Head and Neck Cancer in collaboration with Galapagos NV (Galapagos). It has two pre-clinical programs for the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).
Financial Summary: BRIEF: For the three months ended 31 March 2025, Adaptimmune Therapeutics PLC - ADR revenues increased 28% to $7.3M. Net loss decreased 2% to $47.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Clinical-stage biopharmaceutical segment loss decrease of 7% to $45.7M. Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.03.